Commercial immunotherapy leader ImmunityBio, Inc. (NASDAQ: IBRX) announced on November 9, 2026 that its pivotal randomized Phase 3 clinical trial met its primary efficacy endpoint. The trial evaluated ANKTIVA (nogapendekin alfa inbakicept-pmln) with Bacillus Calmette-Guérin (BCG). It is designated the QUILT-2.005 trial. The study tested the interleukin-15 (IL-15) superagonist complex with standard intravesical BCG.
ANKTIVA plus BCG shows superior disease-free survival in NMIBC
Patients were treatment-naïve and had high-grade non-muscle invasive bladder cancer (NMIBC). The trial showed statistically significant superiority in disease-free survival. That comparison was against standard-of-care BCG monotherapy. The result covers a registrational study population.
Cohort A of the global randomized controlled study enrolled hundreds of BCG-naïve patients with high-risk NMIBC. Enrollment spanned leading international cancer research centers. Senior clinical leadership detailed the outcomes during an investor conference call. The statement was: "Achieving the primary endpoint in the randomized QUILT-2.005 study demonstrates the biological synergy of superagonist IL-15 immunotherapy. This therapeutic combination offers treatment-naïve bladder cancer patients a highly effective pathway to disease eradication while preserving bladder function."
Longitudinal data covered a 24-month monitoring horizon. Patients receiving the ANKTIVA combination experienced durable disease-free intervals. They outperformed BCG monotherapy. The combination did not introduce cumulative systemic toxicities.
ImmunityBio plans sBLA submission to FDA in first half of 2027
ImmunityBio submitted a regulatory Form 8-K disclosure to the United States Securities and Exchange Commission on November 9. The filing detailed trial parameters and primary efficacy endpoints. ANKTIVA previously received regulatory clearance for BCG-unresponsive NMIBC with carcinoma in situ. Successful Phase 3 execution in the front-line BCG-naïve setting addresses a substantially broader commercial patient demographic.
The biopharmaceutical company confirmed it will assemble a supplemental Biologics License Application (sBLA). Formal submission to the United States Food and Drug Administration is planned for the first half of 2027. Clinical oncologists and patient advocacy foundations commended the positive readout. They observed that durable remission in treatment-naïve disease could establish ANKTIVA as the foundational international standard of care in non-muscle invasive bladder cancer.
The randomized QUILT-2.005 study readout positions ImmunityBio's ANKTIVA combination therapy to change front-line clinical practice. The population is patients diagnosed with non-muscle invasive bladder cancer. The regimen showed superior disease-free survival compared to standard BCG monotherapy. It provides a therapeutic alternative that could prevent thousands of radical surgical cystectomies annually.
IL-15 superagonism drives localized anti-tumor immune responses
Oncologists and clinical research directors noted how the therapy works. Activating natural killer cells and memory T cells via interleukin-15 superagonism creates localized anti-tumor immune responses within the bladder epithelium. Regulatory analysts anticipate formal FDA submission of the supplemental Biologics License Application in early 2027. They expect accelerated priority review consideration.
Translational oncology specialists and urological patient advocacy foundations underscored the Phase 3 evidence. Superior disease-free survival is a transformative milestone for bladder cancer care, they said. Continued clinical development of synergistic immunotherapy combinations provides hope for preserving vital organ function. It also provides hope for improving patient outcomes worldwide.
Biopharmaceutical industry observers and clinical investigators underscored that novel immuno-oncology combinations offer hope for cancer patients. The clinical oncology community awaits regulatory filings. Those filings could establish new therapeutic benchmarks for non-muscle invasive bladder cancer.
Investigators emphasize hope from targeted immunotherapy combinations
Clinical oncology investigators emphasized that targeted immunotherapy combinations provide hope for patients facing difficult cancer diagnoses. Medical research centers worldwide expressed strong optimism. They expect upcoming regulatory submissions to pave the way toward delivering new treatments.
Clinical research foundations emphasized that collaborative regulatory partnerships accelerate translation of scientific discoveries into bedside care.
